Skip to main content

GMI-1070: Pan-selectin antagonist treatment of sickle cell disease

Publication ,  Journal Article
Telen, MJ
Published in: Drugs of the Future
June 1, 2012

GMI-1070 is a rationally designed carbohydrate molecule created as an antagonist of all selectin proteins. Selectins are adhesion molecules expressed by many hematopoietic and endothelial cells. They mediate early stages of cell adhesion and are therefore critical in a wide variety of cell-cell interactions, including hematopoietic stem cell interactions with the bone marrow microenvironment, lymphocyte homing to lymphoid tissue, inflammatory leukocyte adhesion to the endothelium, and cancer cell adhesion during metastasis. In sickle cell disease, both red cell and leukocyte adhesion appears to be at least partially selectin-dependent, suggesting that blockade of selectin-mediated interactions might ameliorate or prevent vaso-occlusive events. GMI-1070 has been shown to have activity in many of these processes in a variety of in vitro and in vivo models. In addition, it has been tested in humans in phase I studies, and it is now undergoing phase II evaluation in the setting of sickle cell disease vaso-occlusive events. This compound thus represents one of the earliest attempts at anti-adhesive therapy in sickle cell disease. Copyright © 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

Duke Scholars

Published In

Drugs of the Future

DOI

ISSN

0377-8282

Publication Date

June 1, 2012

Volume

37

Issue

6

Start / End Page

403 / 413

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Telen, M. J. (2012). GMI-1070: Pan-selectin antagonist treatment of sickle cell disease. Drugs of the Future, 37(6), 403–413. https://doi.org/10.1358/dof.2012.37.6.1790307
Telen, M. J. “GMI-1070: Pan-selectin antagonist treatment of sickle cell disease.” Drugs of the Future 37, no. 6 (June 1, 2012): 403–13. https://doi.org/10.1358/dof.2012.37.6.1790307.
Telen MJ. GMI-1070: Pan-selectin antagonist treatment of sickle cell disease. Drugs of the Future. 2012 Jun 1;37(6):403–13.
Telen, M. J. “GMI-1070: Pan-selectin antagonist treatment of sickle cell disease.” Drugs of the Future, vol. 37, no. 6, June 2012, pp. 403–13. Scopus, doi:10.1358/dof.2012.37.6.1790307.
Telen MJ. GMI-1070: Pan-selectin antagonist treatment of sickle cell disease. Drugs of the Future. 2012 Jun 1;37(6):403–413.

Published In

Drugs of the Future

DOI

ISSN

0377-8282

Publication Date

June 1, 2012

Volume

37

Issue

6

Start / End Page

403 / 413

Related Subject Headings

  • Medicinal & Biomolecular Chemistry
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences